Operating
Stock-Based Comp
Bristol-Myers Squibb Stock-Based Comp increased by 9.8% to $146.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.4%, from $144.00M to $146.00M. Over 4 years (FY 2021 to FY 2025), Stock-Based Comp shows relatively stable performance with a -1.3% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026
How to read this metric
Increasing levels may indicate a focus on talent retention but can also signal potential shareholder dilution.
Detailed definition
This represents the value of equity-based awards granted to employees as part of their total compensation package. Since...
Peer comparison
Standard across large-cap corporations; varies based on corporate compensation philosophy.
Metric ID:
stock_based_compensationHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $157.00M | $142.00M | $133.00M | $107.00M | $116.00M | $115.00M | $119.00M | $122.00M | $137.00M | $132.00M | $127.00M | $133.00M | $125.00M | $129.00M | $120.00M | $144.00M | $137.00M | $139.00M | $133.00M | $146.00M |
| QoQ Change | — | -9.6% | -6.3% | -19.5% | +8.4% | -0.9% | +3.5% | +2.5% | +12.3% | -3.6% | -3.8% | +4.7% | -6.0% | +3.2% | -7.0% | +20.0% | -4.9% | +1.5% | -4.3% | +9.8% |
| YoY Change | — | — | — | — | -26.1% | -19.0% | -10.5% | +14.0% | +18.1% | +14.8% | +6.7% | +9.0% | -8.8% | -2.3% | -5.5% | +8.3% | +9.6% | +7.8% | +10.8% | +1.4% |
Range$107.00M – $157.00M
CAGR-1.5%
Avg YoY Growth+1.8%
Median YoY Growth+7.2%
Stock-Based Comp at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's stock-based comp?
- Bristol-Myers Squibb (BMY) reported stock-based comp of $146.00M in Q1 2026.
- How has Bristol-Myers Squibb's stock-based comp changed year-over-year?
- Bristol-Myers Squibb's stock-based comp increased by 1.4% year-over-year, from $144.00M to $146.00M.
- What is the long-term trend for Bristol-Myers Squibb's stock-based comp?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's stock-based comp has grown at a -1.3% compound annual growth rate (CAGR), from $583.00M to $553.00M.
- What does stock-based comp mean?
- The non-cash cost of paying employees with company stock instead of cash.